Antibiotics: Containing the Beta-Lactam Structure Part II / Edition 1

by P. Actor, M.C. Browning, N.H. Georgopapadakou, J.R.E. Hoover, K.C. Kwan

Overview

It is quite amazing that the oldest group of medically useful antibiotics, the fJ-Iactams, are still providing basic microbiologists, biochemists, and clinicians with surprises over 50 years after Fleming's discovery of penicillin production by Penicillium. By the end of the 1950s, the future of the penicillins seemed doubtful as resistant strains of Staphylococcus aureus began to increase in hospital populations. However, the development of semisynthetic penicillins provided new structures with resistance to penicillinase and with broad-spectrum activity. In the 1960s, the discovery of cephalosporin C production by Cephalosporium and its conversion to valuable broad-spectrum antibiotics by semisynthetic means excited the world of chemotherapy. In the early 1970s, the 40-year-old notion that fJ-Iactams were produced only by fungi was destroyed by the discovery of cephamycin production by Streptomyces. Again this basic discovery was exploited by the deVelopment of the semisynthetic cefoxitin, which has even broader activity than earlier fJ-Iactams. Later in the 1970s came the discoveries of nocardicins from Nocardia, clavulanic acid from Streptomyces, and the carbapenems from Streptomyces. Now in the 1980s we learn that fJ-Iactams are produced even by unicellular bacteria and that semisynthetic derivatives of these monobactams may find their way into medicine. Indeed, the future of the prolific fJ-Iactam family seems brighter with each passing decade.

Product Details

ISBN-13:	9783642689031
Publisher:	Springer Berlin Heidelberg
Publication date:	12/06/2011
Series:	Handbook of Experimental Pharmacology , #2
Edition description:	Softcover reprint of the original 1st ed. 1983
Pages:	479
Product dimensions:	6.69(w) x 9.61(h) x 0.04(d)

Table of Contents

12 Bacterial Enzymes Interacting with—-Lactam Antibiotics.- A. Introduction.- B. Bacterial Proteins Binding—-Lactam Antibiotics.- C. Enzymes Inhibited by—-Lactam Antibiotics.- D.—-Lactamases.- E. Interaction with the—-Lactam Nucleus.- F. Concluding Remarks.- References.- 13 In Vitro and In Vivo Laboratory Evaluation of—-Lactam Antibiotics.- A. Historical.- B.—-Lactam Laboratory Evaluation Procedures.- C. Representative—-Lactam Agents.- References.- 14—-Lactam Antibiotics: Structure-Activity Relationships.- A. Introduction: Scope.- B. Clinically Useful Penicillins.- C. Clinically Useful Cephalosporins.- D. Nonclassic—-Lactams.- E. Other Structure-Activity Relationships.- References.- 15 Pharmacokinetics of—-Lactam Antibiotics.- A. Introduction.- B. Penicillins.- C. Cephalosporins.- D. Other—-Lactam Antibiotics.- References.- 16 Toxicology of—-Lactam Antibiotics.- A. Introduction.- B. Local Reactions to Parenteral Administration.- C. Gastrointestinal Side Effects.- D. Immunologically Mediated Toxicity.- E Immune Hemolytic Anemia.- F. Neutropenia.- G. Disorders of Hemostasis.- H. Interstitial Nephritis and Cystitis.- I. Nephrotoxicity.- J. Hepatic Toxicity.- K. Neurotoxicity.- L. Disulfiram-Like Reactions.- M. Newer—-Lactams.- References.- 17 Therapeutic Application of—-Lactam Antibiotics.- A. Introduction.- B. Penicillins in the Therapy of Human Infections.- C. Cephalosporins in the Therapy of Human Infections.- D. Antibacterial Chemoprophylaxis with the—-Lactam Antiobiotics.- E. Use of—-Lactam Antibiotics in Dental Medicine.- F. Use of—-Lactam Antibiotics in Veterinary Practice.- References.